Insights into ASX Stocks
Monadelphous Group (ASX: MND) – From Turnaround Story to Premium-Cycle Pricing
Monadelphous Group is a high-quality, cycle-exposed engineering contractor leveraged to Australian resources and energy capex. Strong cash generation, a net cash balance sheet and disciplined contract selection underpin its reputation and dividend capacity. Long-standing Tier 1 client relationships support earnings resilience across mining, LNG and infrastructure projects. However, the current valuation suggests much of the favourable operating outlook is already priced in.
Has Neuren Pharmaceuticals' (NEU) share price bottomed out?
If you bought Neuren Pharmaceuticals (ASX: NEU) near its peak, the recent volatility has been uncomfortable. Despite having its first approved drug for a rare paediatric disorder, growing royalty income and a promising pipeline, the share price has repeatedly rallied and retraced over the past two years. The key question now is whether NEU has already formed a durable bottom — or if another leg down could still test investor conviction.
Fortescue Ltd (ASX: FMG): Strong Cash Flows and Dividends in a Cyclical Iron Ore Market
Fortescue Ltd is a low-cost iron ore producer with strong cash flow and attractive fully franked dividends, but earnings remain highly exposed to iron ore prices and Chinese demand. Trading around mid-cycle valuation levels, the stock looks fairly valued, with upside dependent on stronger commodity prices and successful expansion into magnetite and green energy.
WiseTech Global (ASX: WTC) – Testing the $2bn Strategic Gamble
WiseTech Global’s A$2bn acquisition of E2open has significantly boosted revenue but diluted margins and increased leverage, shifting the investment case from premium organic growth to execution-driven integration. While the long-term strategic rationale remains sound, near-term earnings pressure and higher balance sheet risk make valuation more demanding and leave little room for integration missteps.
Has PolyNovo's (ASX: PNV) share price hit the bottom yet?
PolyNovo Limited (ASX: PNV) remains a fundamentally strong, high-growth medtech, but its share price is currently testing key support around A$0.88–0.92 within a broader sideways range. While selling pressure has eased and momentum is stabilising, a confirmed bottom would require a sustained break above A$1.08; otherwise, a fall below A$0.86–0.90 could signal further downside.
Westpac Banking Corporation (ASX: WBC) – Capital Strength and Dividend Appeal in a Low-Growth Environment
Westpac Banking Corporation is a systemically important bank with a strong mortgage franchise, solid capital buffers and a fully franked dividend. With modest 3–4% earnings growth expected, current valuations look full, making it more suited to income investors than deep-value buyers.